Medifast (NYSE:MED - Get Free Report) issued an update on its second quarter 2025 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of -0.550-0.000 for the period, compared to the consensus estimate of -0.070. The company issued revenue guidance of $85.0 million-$105.0 million, compared to the consensus revenue estimate of $112.3 million.
Analyst Upgrades and Downgrades
MED has been the topic of several analyst reports. DA Davidson cut their price target on shares of Medifast from $17.00 to $16.50 and set a "neutral" rating on the stock in a report on Wednesday, February 19th. StockNews.com upgraded Medifast from a "hold" rating to a "buy" rating in a research note on Thursday.
Get Our Latest Stock Report on Medifast
Medifast Stock Performance
NYSE:MED traded up $0.29 during trading on Friday, reaching $13.27. The company's stock had a trading volume of 266,292 shares, compared to its average volume of 307,303. Medifast has a 12 month low of $11.57 and a 12 month high of $27.18. The firm has a market cap of $145.85 million, a price-to-earnings ratio of 73.72 and a beta of 1.05. The firm has a 50 day moving average of $13.38 and a 200-day moving average of $15.99.
Medifast (NYSE:MED - Get Free Report) last issued its quarterly earnings results on Monday, April 28th. The specialty retailer reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.04). Medifast had a return on equity of 10.64% and a net margin of 0.35%. The company had revenue of $115.73 million during the quarter, compared to analysts' expectations of $114.85 million. Equities research analysts forecast that Medifast will post 0.51 earnings per share for the current fiscal year.
Medifast Company Profile
(
Get Free Report)
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Featured Stories
Before you consider Medifast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.
While Medifast currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
